Stimpel M, Cawello W. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: is coadministration with food of clinical relevance? Hypertension (1995) 25, 1384.
Lee DJ, Lowe G. Interaction of alcohol and caffeine in a perceptual-motor task. IRCS Med Sci (1980) 8, 420.
Reynolds WA, Lowe FH. Mushrooms and a toxic reaction to alcohol: report of four cases. N Engl J Med (1965) 272, 630–1.
Wildervanck LS. Alcohol en de kale inktzwam. Ned Tijdschr Geneeskd (1978) 122, 913–14.
Buck RW. Mushroom toxins—a brief review of the literature. N Engl J Med (1961) 265, 681–6.
Marty H. Von Pilzen und Schnäpsen. Schweiz Med Wochenschr (1998) 128, 598.
Flammer R. Brechdurchfälle als Leitsymptom – Pilze und Alkohol. Emesis and diarrhea – mushrooms and alcohol. Schweiz Rundsch Med Prax (1985) 74, 992–6.
Oteo Revuelta JA, Grandival García R, Olarte Arce A. Reaccíon disulfiram-like por ingesta de hongos [Disulfiram-like reaction caused by mushroom ingestion]. Rev Clin Esp (1989) 184, 394–5.
Budmiger H, Kocher F. Hexenröhrling (Boletus luridus) mit Alkohol: ein kasuistischer beitrag. Schweiz Med Wochenschr (1982) 112, 1179–81.
Simandl J, Franc J. Isolace tetraethylthiuramdisulfidu z hníku inko ustového (Coprinus atramentarius). Chem Listy (1956) 50, 1862–3.
Lee FC, Ko JH, Park KJ, Lee JS. Effect of Panax ginseng on blood alcohol clearance in man. Clin Exp Pharmacol Physiol (1987) 14, 543–6.
Choi CW, Lee SI, Huh K. Effect of ginseng on the hepatic alcohol metabolizing enzyme system activity in chronic alcohol-treated mice. Korean J Pharmacol (1984) 20, 13–21.
Herberg K-W. Zum Einfluß von Kava-Spezialextrakt WS 1490 in Kombination mit Ethylalkohol auf sicherheitsrelevante Leistungsparameter. The influence of kava-special extract WS 1490 on safety-relevant performance alone and in combination with ethyl alcohol. Blutalkohol (1993) 30, 96–105.
Hiller K-O, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L.; behavioural and anticonvulsant properties. Phytother Res (1996) 10,145–51.
Sioufi A, Stierlin H, Schweizer A, Botta L, Degen PH, Theobald W, Brechbühler S. Recent findings concerning clinically relevant pharmacokinetics of diclofenac sodium. In: Voltarol — New Findings, ed Kass E Proc Int Symp Voltarol, Paris June 22nd (1981). 15th Int Congress of Rheumatology. p 19–30.
Troy S, Sanda M, Dressler D, Chiang S, Latts J. The effect of food and antacid on etodolac bioavailability. Clin Pharmacol Ther (1990) 47, 192.
Levine MA, Walker SE, Paton TW. The effect of food or sucralfate on the bioavailability of S(+) and R(-) enantiomers of ibuprofen. J Clin Pharmacol (1992) 32, 1110–14.
Eshra AG, Etman MA, Naggar VF. Effect of milk and food on the bioavailability of ketoprofen in man. Int J Pharmaceutics (1988) 44, 9–14.
Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: non-invasive assessment by use of papillary miosis. Clin Pharmacol Ther (2004) 76, 452–66.
Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther (2004) 76, 250–69.
Hardin J, Lange D, Heykants J, Ding C, Van de Velde V, Slusser C, Klausner M. The effect of co-administration of a cola beverage on the bioavailability of itraconazole in AIDS patients. Intersci Conf Antimicrob Agents Chemother (1995) 35, 6.
Lange D, Pavao JH, Wu J, Klausner M. Effect of cola beverage on the bioavailability of itraconazole in the presence of H 2 blockers. J Clin Pharmacol (1997) 37, 535–40.
Carver P, Welage L, Kauffman C. The effect of food and gastric pH on the oral bioavailability of itraconazole in HIV+ patients. Intersci Conf Antimicrob Agents Chemother (1996) 36, 6.
Courtney R, Sansone A, Calzetta A, Martinho M, Laughlin. The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole. Intersci Conf Antimicrob Agents Chemother (2003) 43, 33.
Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bio-availability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol (2004) 57, 218–22.
Bindschedler M, et al. Comparative bioavailability of benflumetol after administration of single oral doses of co-artemether under fed and fasted conditions to healthy subjects. Cited in Lefèvre G, Thomsen MS. Clinical Pharmacokinetics of artemether and lumefantrine (Riamet®). Clin Drug Invest (1999) 18, 467–80.
Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, Hohl RJ, Fleckenstein L. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clin Pharmacol Ther (2003) 73, P94.
Munoz CE, Ito S, Bend JR, Tesoro A, Freeman D, Spence JD, Bailey DG. Propafenone interaction with CYP3A4 inhibitors in man. Clin Pharmacol Ther (1997) 61, 154.
Melander A, Danielson K, Hanson A, Jansson L, Rerup C, Scherstén B, Thulin T, Wåhlin E. Reduction of isoniazid bioavailability in normal men by concomitant intake of food. Acta Med Scand (1976) 200, 93–7.
Uragoda CG, Lodha SC. Histamine intoxication in a tuberculous patient after ingestion of cheese. Tubercle (1979) 60, 59–61.
Toutoungi M, Carroll R, Dick P. Isoniazide (INH) and tyramine-rich food. Chest (1986) 89 (Suppl 6), 540S.
Senanayake N, Vyravanathan S, Kanagasuriyam S. Cerebrovascular accident after a ‘skipjack’ reaction in a patient taking isoniazid. BMJ (1978) 2, 1127–8.
Senanayake N, Vyravanathan S. Histamine reactions due to ingestion of tuna fish (Thunus argentivittatus) in patients on antituberculosis therapy. Toxicon (1981) 19, 184–5.
Morinaga S, Kawasaki A, Hirata H, Suzuki S, Mizushima Y. Histamine poisoning after ingestion of spoiled raw tuna in a patient taking isoniazid. Intern Med (1997) 36, 198–200.
Uragoda CG. Histamine intoxication with isoniazid and a species of fish. Ceylon Med J (1978) 23, 109–10.
Miki M, Ishikawa T, Okayama H. An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in a tuberculous ward. Intern Med (2005) 44, 1133–6.
Diao Y et al. Histamine like reaction in tuberculosis patients taking fishes containing much of histamine under treatment with isoniazid in 277 cases. Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi (1986) 9, 267–9, 317–18.
Nguyen M, Beringer P, Wong-Beringer A, Louie S, Gill M, Gurevitch A. Effect of continuous enteral feedings (TF) on oral bioavailability (F) of linezolid (LZD) in hospitalized patients. Abstracts of the 43 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Il (2003), 43, 36.
Magni L, Sjöberg B, Sjövall J, Wessman J. Clinical pharmacological studies with bacampicillin. Chemotherapy (1976) 5, 109–114.
Ali HM. The effect of Sudanese food and chloroquine on the bioavailability of ampicillin from bacampicillin tablets. Int J Pharmaceutics (1981) 9, 185–90.
Bergdahl S, Eriksson M, Finkel Y, Lännergren K. Oral absorption of flucloxacillin in infants and young children. Acta Pharmacol Toxicol (Copenh) (1986) 58, 255–8.
Fernandez CA, Menezes JP, Ximenes J. The effect of food on the absorption of pivampicillin and a comparison with the absorption of ampicillin potassium. J Int Med Res (1973) 1, 530–3.
Bertino JS, Nafziger AN, Wong M, Stragand L, Puleo C. Effects of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses. Antimicrob Agents Chemother (1994) 38, 499–503.
Shiba K, Kusajima H, Momo K. The effects of aluminium hydroxide, cimetidine, ferrous sulfate, green tea and milk on pharmacokinetics of gatifloxacin in healthy humans. J Antimicrob Chemother (1999) 44 (Suppl A), 141.
Noer BL, Angaran DM. The effect of enteral feedings on ciprofloxacin pharmacokinetics. Pharmacotherapy (1990) 10, 254.
Sowinski KM, Abel SR, Clark WR, Mueller BA. Effect of gender on relative oral bioavailability of ciprofloxacin and ofloxacin when administered with an enteral feeding product. Pharmacotherapy (1997) 17, 1112.
Höffken G, Lode H, Wiley R, Glatzel TD, Sievers D, Olschewski T, Borner K, Koeppe T. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis (1988) 10 (Suppl 1), S138–S139.
Mattila MJ, Neuvonen PJ, Gothoni G, Hackman CR. Interference of iron preparations and milk with the absorption of tetracyclines. Int Congr Ser (1972) 254, 128–33.
Siewert M, Blume H, Stenzhorn G, Kieferndorf U, Lenhard G. Zur Qualitätsbeurteilung von doxycyclinhaltigen ertigarzneimitteln.3. Mitteilung: Vergleichende Bioverfügbarkeitsstudie unter Berücksichtigung einer Einnahme mit Milch. Pharm Ztg (1990) 3, 96–102.
Isele H. Tödliche Blutung unter Warfarin plus Preiselbeersaft. Liegt’s an der Salizylsäure? MMW Fortschr Med (2004) 146, 13.
Simon LS, Likes KE. Hypoprothrombinemic response due to ice cream. Drug Intell Clin Pharm (1978) 12, 121–2.
Blackshaw CA, Watson VA. Interaction between warfarin and ice cream. Pharm J (1990) 244, 318.
Michaelson R, Kempin SJ, Navia B, Gold JWM. Inhibition of the hypoprothrombinemic effect of warfarin (Coumadin ® ) by Ensure-Plus, a dietary supplement. Clin Bull (1980) 10, 171–2.
Griffith LD, Olvey SE, Triplett WC, Stotter Cuddy ML. Increasing prothrombin times in a warfarin-treated patient upon withdrawal of Ensure Plus. Crit Care Med (1982) 10, 799–800.
Van Iersel MB, Blenke AAM, Kremer HPH, Hekster YA. Een patiënt met verminderde gevoeligheid voor acenocoumarol tijdens gebruik van sondevoeding. Ned Tijdschr Geneeskd (2004) 148, 1155–6.
Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil (2001) 82, 1270–3.
Schurgers LJ, Shearer MJ, Hamulyák K, Stöcklin E, Vermeer C. Effect of vitamin K intake onthe stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood (2004) 104, 2682–9.
Gaddi A, Sangiorgi Z, Ciarrocchi A, Braiato A, Descovich GC. Hypocholesterolemic soy protein diet and resistance to warfarin therapy. Curr Ther Res (1989) 45, 1006–10.
Booth SL, Madabushi HT, Davidson KW, Sadowski JA. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). J Am Diet Assoc (1995) 95, 82–3.
Ovesen L, Lyduch S, Idorn ML. The effect of a diet rich in brussel sprouts on warfarin pharmacokinetics. Eur J Clin Pharmacol (1988) 33, 521–3.
Anon. Leafy vegetables in diet alter prothrombin time in patients taking anticoagulant drugs. JAMA (1964) 187, 27.
van Rooij J, van der Meer FJM, Schoemaker HC, Cohen AF. Comparison of the effect of grapefruit juice and cimetidine on pharmacokinetics and anticoagulant effect of a single dose of acenocoumarol. Br J Clin Pharmacol (1993) 35, 548P.
Dresser GK, Munoz C, Cruikshank M, Kovacs M, Spence JD. Grapefruit juice-warfarin interaction in anticoagulated patients. Clin Pharmacol Ther (1999) 65, 193.
Lo ACT, Chan K, Yeung JHK, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and dynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet (1992) 17, 257–62.
Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy (1999) 19, 870–6.
Ellis GR, Stephens MR. Untitled report. BMJ (1999) 319, 650.
Sunter W. Warfarin and garlic. Pharm J (1991) 246, 722.
Shalansky S, Neall E, Lo M, Abd-Elmessih E, Vickars L, Lynd L. The impact of complementary and alternative medicine use on warfarin-related adverse outcomes. Pharmacotherapy (2002) 22, 1345.
Argento A, Tiraferri E, Marzaloni M. Anticoagulanti orali e piante medicinali. Una interazione emergente. Ann Ital Med Int (2000) 15, 139–43.
Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q 10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost (2002) 87, 1075–6.
Lai C-F, Chang C-C, Fu C-H, Chen C-M. Evaluation of the interaction between warfarin and ginkgo biloba extract. Pharmacotherapy (2002) 22, 1326.
Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology (2003) 99, 111.
Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, Langheinrich M, Hübner W-D. Interaction of St John’s wort extract with phenprocoumon. Eur J Clin Pharmacol (1999) 55, A22.
Bon S, Hartmann, Kuhn M. Johanniskraut: Ein Enzyminduktor? Schweiz Apothekerzeitung (1999) 16, 535–6.
Bransgrove LL. Interaction between warfarin and a vitamin K-containing nutritional supplement: a case report. J Herb Pharmacother (2001) 1, 85–89.
Iven H, Lerche L, Kaschube M. Influence of quinine and quinidine on the pharmacokinetics of phenprocoumon in rat and man. Eur J Pharmacol (1990) 183, 662.
Clark DJ. Clinical curio: warfarin and tonic water. BMJ (1983) 286, 1258.
Pirk LA, Engelberg R. Hypoprothrombinemic action of quinine sulfate. JAMA (1945) 128, 1093–5.
Page RC, de Beer EJ, Orr ML. Prothrombin studies using Russell viper venom. II.Relation of clotting time to prothrombin concentration in human plasma. J Lab Clin Med (1941) 27, 197–201.
Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, Venkaiah K, Raval BH. Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother Res (1993) 7, 285–9.
Hulin A, Wavelet M, Desbordes JM. Intoxication aiguë par Momordica charantia (sorrossi). A propos de deux cas. Sem Hop Paris (1988) 64, 2847–8.
Hruska MW, Cheong JA, Langaee TY, Frye RF. Effect of St John’s wort administration on CYP2C8 mediated rosiglitazone metabolism. Clin Pharmacol Ther (2005) 77, P35.
Senzaki A, Okubo Y, Matuura M, Kojima T, Toru M. Clinical studies on effects of Saiko-ka-ryukotsu-borei-to (TJ-12) for adult patients with symptomatic localization-related epilepsy. Rinsho Seishin Igaku (1993) 22, 641–6.
Chen LC, Chou MH, Lin MF, Yang LL. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. J Clin Pharm Ther (2000) 25, 453–9.
Sekikawa H, Nakano M, Takada M, Arita T. Influence of dietary components on the bioavailability of phenytoin. Chem Pharm Bull (Tokyo) (1980) 28, 2443–9.
Marvel ME, Bertino JS. Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. J Parenter Enteral Nutr (1991) 15, 316–8.
Pearce GA. Apparent inhibition of phenytoin absorption by an enteral nutrient formula. Aust J Hosp Pharm (1988) 18, 289–92.
Gilbert S. How to minimize interaction between phenytoin and enteral feedings: two approaches. A Strategic approach. Nutr Clin Pract (1996) 11, 28–30.
Hatton J, Magnuson B. How to minimize interaction between phenytoin and enteral feedings: two approaches. B Therapeutic options. Nutr Clin Pract (1996) 11, 30–1.
Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet (2002) 41, 311–18.
Dresser GK, Kim RB, Bailey DG. Duration of grapefruit juice effect on fexofenadine interaction. Clin Pharmacol Ther (2003) 73, P48.
Anon. Grapefruit juice and terfenadine: the “final straw”. Pharm J (1997) 258, 618.
Schneider W, Krumpl G, Mayer N, Raberger G. The effects of nitroglycerin on exercise-induced regional myocardial contractile dysfunction are not diminished by pretreatment with dihydroergotamine. Br J Pharmacol (1987) 92, 87–95.
Warmuth-Metz M. Ergotismus der unteren Extremität als Folge einer DHE-Heparin-Thrombose prophylaxe. Radiologe (1988) 28, 491–3.
Jahn R. Ergotismus – ein Risiko bei der Thromboseprophylaxe? Zentralbl Chir (1985) 110, 482–5.
Lagier G, Castot A, Riboulet G, Boesh C. Un cas d’ergotisme mineur semblant en rapport avec une potentialisation de l’ergotamine par l’éthylsuccinate d’érythromycine. Therapie (1979) 34, 515–21.
Neveux E, Lesgourgues B, Luton J-P, Guilhaume B, Bertagna, Picard J. Ergotisme aigu par association proprionate d’érythromycine-dihydroergotamine. Nouv Presse Med (1981) 10, 2830.
Collet AM, Moncharmont D, San Marco JL, Eissinger F, Pinot JJ, Laselve L. Ergotisme iatrogène: rôle de l’association tartrate d’ergotamine-propionate d’érythromycine. Sem Hop Paris (1982) 58, 1624–6.
Boucharlat J, Franco A, Carpentier P, Charignon Y, Denis B, Hommel M. Ergotisme en milieu psychiatrique par association D.H.E.propionate d’erythromycine. A propos d’une observation. Ann Med Psychol (Paris) (1980) 138, 292–6
Grolleau JY, Martin M, de la Guerrande B, Barrier J, Peltier P. Ergotism aigu lors d’une association josamycine/tartrate d’ergotamine. Therapie (1981) 36, 319–21.
Monsarrat M, Lefebvre D, Parraguette J, Vaysse C, Bastide G. Ergotisme aigu par association ergotamine-oleandomycine. Nouv Presse Med (1982) 11, 603.
Franco A, Bourlard P, Massot C, Lecoeur J, Guidicelli H, Bessard G. Ergotisme aigu par association dihydroergotamine-triacétyloléandomycine. Nouv Presse Med (1978) 7, 205.
Lesca H, Ossard D, Reynier P. Les risques de l’association tri-acétyl-oléandomycine et tartrate d’ergotamine. Nouv Presse Med (1976) 5, 1832–3.
Dupuy JC, Lardy P, Seaulau P, Kervoelen P, Paulet J. Spasmes artériels systémiques. Tartrate d’ergotamine. Arch Mal Coeur (1979) 72, 86–91.
Bigorie B, Aimez P, Soria RJ, Samama F di Maria G, Guy-Grand B, Bour H. L’association triacétyl oléandomycin-tartrate d’ergotamine est-elle dangereuse? Nouv Presse Med (1975) 4, 2723–5.
Vayssairat M, Fiessinger J-N, Becquemin M-H, Housset E. Association dihydroergotamine et triacétyloléandomycine. Rôle dans une nécrose digitale iatrogène. Nouv Presse Med (1978) 7, 2077.
Chignier E, Riou R, Descotes J, Meunier P, Courpron P, Vignon G. Ergotisme iatrogène aigu par association médicamenteuse diagnostiqué par exploration non invasive (vélocimétrie à effet Doppler). Nouv Presse Med (1978) 7, 2478.
Bacourt F, Couffinhal J-C. Ischémie des membres par association dihydroergotamine-tri-acétyloléandomycine. Nouvelle observation. Nouv Presse Med (1978) 7, 1561.
Baudouy PY, Mellat M, Velleteau de Moulliac M. Infarctus du myocarde provoqué par l’association tartrate d’ergotamine-troléandomycine. Rev Med Interne (1988) 9, 420–2.
Caballero-Granado FJ, Viciana P, Cordero E, Gómez-Vera MJ, del Nozal M, López-Cortés LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrob Agents Chemother (1997), 41,1207.
Montero A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritonavir and ergotamine. Ann Intern Med (1999) 130, 329–30.
Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. Postgrad Med J (1999) 75, 546–7.
Amblard P, Reymond JL, Franco A, Beani JC, Carpentier P, Lemonnier D, Bessard G. Ergotisme. Forme mineure par association dihydroergotamine-chlorhydrate de doxycycline, étude capillaroscopique. Nouv Presse Med (1978) 7, 4148–9.
Dupuy JC, Lardy P, Seaulau P, Kervoelen P, Paulet J. Spasmes artériels systémiques. Tartrate d’ergotamine. Arch Mal Coeur (1979) 72, 86–91.
Van Gestel R, Noirhomme Ph. Ergotism aigu par association de tartrate d’ergotamine et de doxycycline. Louvain Med (1984) 103, 207–208.
L’Yvonnet M, Boillot A, Jacquet AM, Barale F, Grandmottet P, Zurlinden B, Gillet JY. A propos d’un cas exceptionnel d’intoxication aigue par un dérivé de l’ergot de seigle. Gynecologie (1974) 25, 541–3.
Sibertin-Blanc M. Les dangers de l’ergotisme a propos de deux observations. Arch Med Ouest (1977) 9, 265–6.
Eagon CL, Elm MS, Teepe AG, Eagon PK. Medicinal botanicals: estrogenicity in rat uterus and liver. Proc Am Assoc Cancer Res (1997) 38, 293.
Takeishi Y, Tono-oka I, Kubota I, Ikeda K, Masakane I, Chiba J, Abe S, Tsuiki K, Tomoike H. Intravenous aminophylline affects myocardial washout of thallium-201 after dipyridamole infusion. Am J Noninvasive Cardiol (1992) 6, 116–21.
Picano E et al. on behalf of the Echo-Persantine International Cooperative Study Group. Safety of intravenous high-dose dipyridamole echocardiography. Am J Cardiol (1992) 70, 252–8.
Gaillard J-M, Sovilla J-Y, Blois R. The effects of clonazepam, caffeine and the combination of the two drugs on human sleep. In: Koella WP, Rüther E, Schulz H, eds.Sleep ‘84. New York: Gustav Fischer Verlag; (1985): pp. 314–15.
Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol (1998) 18, 311–16.
Beale MD, Pritchett JT, Kellner CH. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Convuls Ther (1994) 10, 228–31.
Lane H-Y, Jann MW, Chang Y-C, Chiu C-C, Huang M-C, Lee S-H, Chang W-H. Repeated ingestion of grapefruit juice does not alter clozapine’s steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry (2001) 62, 812–17.
Stone JA, Ju WD, Steritt A, Woolf EJ, Yeh KC, Deutsch P, Waldman S, Bjornsson TD. Effect of food on the pharmacokinetics of indinavir in man. Pharm Res (1996) 13 (Suppl 9), S414.
Quart BD, Chapman SK, Peterkin J, Webber S, Oliver S. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343--a novel HIV protease inhibitor. The American Society for Microbiology in collaboration with NIH and CDC, 2 nd National Conference Human Retroviruses and Related Infections, Washington DC (1995). Abstract LB3.
Bertz R, Shi H, Cavanaugh J, Hsu A. Effect of three vehicles, Advera ® , Ensure ® and chocolate milk, on the bioavailability of an oral liquid formulation of Norvir (Ritonavir). Intersci Conf Antimicrob Agents Chemother (1996) 36, 5.
Jacek H, Rentsch KM, Steinert HC, Pauli-Magnus C, Meier PJ, Fattinger K. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test. Clin Pharmacol Ther (2004) 75, P80.
Laroche M, Choudhri S, Gallicano K, Foster B. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can J Infect Dis (1998) 9 (Suppl A), 76A.
McCrea J, Woolf E, Sterrett A, Matthews C, Deutsch P, Yeh KC, Waldman S, Bjornsson T. Effects of ketoconazole and other P-450 inhibitors on the pharmacokinetics of indinavir. Pharm Res (1996) 13 (Suppl 9), S485.
Wynn H, Shelton MJ, Bartos L, Difrancesco R, Hewitt RG. Grapefruit juice (GJ) increases gastric pH, but does not affect indinavir (IDV) exposure, in HIV patients. Intersci Conf Antimicrob Agents Chemother (1999) 39, 25.
Barnwell SG, Laudanski T, Dwyer M, Story MJ, Guard P, Cole S, Attwood D. Reduced bioavailability of atenolol in man: the role of bile acids. Int J Pharmaceutics (1993) 89, 245–50.
Smits P, Hoffmann H, Thien T, Houben H, van’t Laar A. Hemodynamic and humoral effects of coffee after β 1 -selective and nonselective β -blockade. Clin Pharmacol Ther (1983) 34, 153–8.
Freestone S, Ramsey LE. Effect of β -blockade on the pressor response to coffee plus smoking in patients with mild hypertension. Drugs (1983) 25 (Suppl 2), 141–5.
Edgar B, Bailey DG, Bergstrand R, Johnsson G, Lurje L. Formulation dependent interaction between felodipine and grapefruit juice. Clin Pharmacol Ther (1990) 47, 181.
Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol (1993) 36, 460–3.
Pisarïk P. Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Arch Fam Med (1996) 5, 413–6.
Fuhr U, Maier A, Blume H, Mück W, Unger S, Staib AH. Grapefruit juice increases oral nimodipine bioavailability. Eur J Clin Pharmacol (1994) 47, A100.
Adigun AQ, Mudasiru Z. Clinical effects of grapefruit juice-nifedipine interaction in a 54-year-old Nigerian: a case report. J Natl Med Assoc (2002) 94, 276–8.
Walan A, Bergdahl B, Skoog M-L. Study of digoxin bioavailability during treatment with a bulk forming laxative (Metamucil). Scand J Gastroenterol (1977) 12 (Suppl 45), 111.
Scheinhost ME. Digoxin toxicity in a 26-year-old woman taking a herbal dietary supplement. J Am Osteopath Assoc (2001), 101, 444–6.
McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. Can Med Assoc J (1996) 155, 293–5.
Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton JL, Annesley T, Aaronson KD, Bleske BE. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol (2003) 43, 637–42.
And elić S. Bigeminija – rezultat interakcije digoksina i kantariona. Vojnosanit Pregl (2003) 60, 361–4.
Verburg FA, van Zanten RAA, Brouwer RML, Woittiez AJJ, Veneman TF. Een man met een ernstig klassiek melk-alkalisyndroom en een maagcarcinoom. Ned Tijdschr Geneeskd (2006) 150, 1624–7.
Picolos MK, Lavis VR, Orlander PR. Milk–alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) (2005) 63, 566–76.
Johnston PE, Milstone A. Probable interaction of bergamottin and cyclosporine in a lung transplant recipient. Transplantation (2005) 79, 746.
Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, Milstone A. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol (2005) 62, 485–91.
Proppe D, Visser K, Hoch O, Bartels R, Meier H, McLean AJ. Differential influence on cyclosporin A metabolism by chronic grapefruit juice exposure. Eur J Clin Invest (1996) 26 (Suppl 1), A20.
Yee GC, Adams VR, Pessa L, Braddock RJ, Ruiz J, Lowenthal DT. Comparison of one versus two doses of grapefruit juice on oral cyclosporine pharmacokinetics. Pharmacotherapy (1997) 17, 1112.
Proppe D, Visser K, Bartels R, Hoch O, Meyer H, McLean AJ. Grapefruit juice selectively modifies cyclosporin A metabolite patterns in renal transplant patients. Clin Pharmacol Ther (1996) 59, 138.
Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H. Effect of grapefruit juice on Sandimmun Neoral ® absorption among stable renal allograft recipients. Nephrol Dial Transplant (2001) 16, 373–7.
Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther (2006) 79, 255–62.
Prasad GVR, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation (2002) 74, 1200–1.
Karliova M, Treichel U, Malagò M, Frilling A, Gerken G, Broelsch CE. Interaction of hypericum perforatum (St John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol (2000) 33, 853–5.
Bon S, Hartmann K, Kuhn M. Johanniskraut: ein enzyminducktor? Schweiz Apothekerzeitung (1999) 16, 535–6.
Ojima M, Satoh K, Gomibuchi T, Itoh N, Kin S, Fukuchi S, Miyachi Y. The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone_—in vivo and in vitro studies. Nippon Naibunpi Gakkai Zasshi (1990) 66, 584–96.
Westveer MK, Farquhar ML, George P, Mayes JT. Co-administration of grapefruit juice increases tacrolimus levels in liver transplant patients. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicians (1996). Abstract P-115.
Michelangelo V, Piero D, Elisa C, Enrico S, Mauro B, Pietro B. Grapefruit juice and kinetics of tacrolimus. J Am Soc Nephrol (2001) 12, 862A.
Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, Oike F, Takada Y, Inui K-I. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab Pharmacokinet (2006) 21, 122–5.
Egashira K, Fukuda E, Onga T, Yogi Y, Matsuya F, Koyabu N, Ohtani H, Sawada Y. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation (2003) 75, 1057.
Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, Sawada Y. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos (2004) 32, 828–33.
Bikin D, Conrad KA, Mayersohn M. Lack of influence of caffeine and aspirin on lithium elimination. Clin Res (1982) 30, 249A.
Pohl R, Balon R, Berchou R. Reaction to chicken nuggets in a patient taking an MAOI. Am J Psychiatry (1988) 145, 651.
Generali JA, Hogan LC, McFarlane M, Schwab S, Hartman CR. Hypertensive crisis resulting from avocados and a MAO inhibitor. Drug Intell Clin Pharm (1981) 15, 904–6.
Boulton AA, Cookson B, Paulton R. Hypertensive crisis in a patient on MAOI antidepressants following a meal of beef liver. Can Med Assoc J (1970) 102, 1394–5.
Comfort A. Hypertensive reaction to New Zealand prickly spinach in a woman taking phenelzine. Lancet (1981) ii, 472.
Korn A, Eichler HG, Fischbach R, Gasic S. Moclobemide, a new reversible MAO inhibitor – interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology (Berl) (1986) 88, 153–7.
Tipton KF, Dostert P, Strolin Benedetti M, eds. Monoamine Oxidase and Disease: Pressor amines and monoamine oxidase inhibitors. London: Academic Press; (1984). p. 429–41.
Shulman KI, Walker SE. Clarifying the safety of the MAOI diet and pizza: reply. J Clin Psychiatry (2000) 61, 145–6.
Da Prada M, Zürcher G. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology (Berl) (1992) 106, S32–S34.
Sen NP. Analysis and significance of tyramine in foods. J Food Sci (1969) 34, 22–26.
Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and the active component, naringenin on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol (1993) 35, 431–6. [Title corrected by erratum].
Meyer FP, Canzler E, Giers H, Walther H. Langzeituntersuchung zum Einfluß von Non-Ovlon auf die Pharmakokinetik von Coffein im intraindividuellen Vergleich. Zentralbl Gynakol (1988) 110, 1449–54.
Evreux JC, Bayere JJ, Descotes J, Lery N, Ollagnier M, Brazier JL. Les accidents neuro-psychiques de l’idrocilamide: conséquence d’une inhibition due métabolisme de la caféine? Lyon Med (1979) 241, 89–91.
Mays DC, Camisa C, Cheney P, Pacula CM, Nawoot S, Gerber N. Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. Clin Pharmacol Ther (1987) 42, 621–6.
Tantcheva-Poór I, Servera-Llaneras M, Scharffetter-Kochanek K, Fuhr U. Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients. Br J Dermatol (2001) 144, 1127–32.
Peloquin CA, Nix DE, Sedman AJ, Wilton JH, Toothaker RD, Harrison NJ, Schentag JJ. Pharmacokinetics and clinical effects of caffeine alone and in combination with oral enoxacin. Rev Infect Dis (1989) II (Suppl 5), S1095.
LeBel M, Teng R, Dogolo LC, Willavize S, Friedman HL, Vincent J. The influence of steady-state trovafloxacin on the steady-state pharmacokinetics of caffeine in healthy subjects. Pharm Res (1996) 13 (Suppl 9), S434.
Randinitis EJ, Koup JR, Rausch G, Vassos AB. Effect of (CLX) administration on the single-dose pharmacokinetics of theophylline and caffeine. Intersci Conf Antimicrob Agents Chemother (1998) 38, 6.
Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of cytochrome P450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos (1990) 18, 1005–10.
Nawoot S, Wong D, Mays DC, Gerber N. Inhibition of caffeine elimination by verapamil. Clin Pharmacol Ther (1988) 43, 148.
Vaughan L, Milavetz G, Hill M, Weinberger M, Hendeles L. Food-induced dose-dumping of Theo-24, a ‘once-daily’ slow-release theophylline product. Drug Intell Clin Pharm (1984) 18, 510.
Fassihi AR, Dowse R, Robertson SSD. Effect of dietary cellulose on the absorption and bioavailability of theophylline. Int J Pharmaceutics (1989) 50, 79–82.
Bouraoui A, Toumi A, Bouchahcha S, Boukef K, Brazier JL. Influence de l’alimentation épicée et piquante sur l’absorption de la théophylline. Therapie (1986) 41, 467–71.
Ziegenbein RC. Theophylline clearance increase from increased amino acid in a CPN regimen. Drug Intell Clin Pharm (1987) 21, 220–1.
Kleman MI, Overvik E, Poellinger L, Gustafsson JA. Induction of cytochrome P4501A isoenzymes by heterocyclic amines and other food-derived compounds. Princess Takamatsu Symp (1995) 23, 163–71.
Kappas A, Alvares AP, Anderson KE, Pantuck EJ, Pantuck CB, Chang R, Conney AH. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin Pharmacol Ther (1979) 23, 445–50.
Peng W-X, Li H-D, Zhou H-H. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. Eur J Clin Pharmacol (2002) 59, 237–41.
Lee AJ, Chan WK, Harralson AF, Buffum J, Bui B-CC. The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin Ther (1999) 21, 1890–9.
Barbenel DM, Yusufi B, O’Shea D, Bench CJ. Mania in a patient receiving testosterone replacement post-orchidectomy taking St John’s wort and sertraline. J Psychopharmacol (2000) 14, 84–6.
Demott K. St. John’s wort tied to serotonin syndrome. Clin Psychiatry News (1998) 26, 28.
Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB. Coma in a patient with Alzheimer’s disease taking low dose trazodone and ginkgo biloba. J Neurol Neurosurg Psychiatry (2000) 68, 679–80.
Abernethy DR, Divoll M, Greenblatt DJ, Shader RI. Imipramine pharmacokinetics and absolute bioavailability: effect of food. Clin Res (1983) 31, 626A.
Vandel P, Regina W, Reix I, Vandel S, Sechter D, Bizouard P. Faut-il contre-indiquer le jus de pamplemousse?Une approche en psychiatrie.[Grapefruit juice as a contraindication?An approach in psychiatry]. Encephale (1999) 25, 67–71.
Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. BMJ (1992) 304, 1686.
Holman CP, Bell AFJ. A trial of evening primrose oil in the treatment of chronic schizophrenia. J Orthomol Psychiatry (1983) 12, 302–4.
Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. Prostaglandins Med (1981) 6, 375–9.
Vaddadi KS, Horrobin DF. Weight loss produced by evening primrose oil administration in normal and schizophrenic individuals. IRCS Med Sci (1979) 7, 52.
Koren G, Boichis H, Keren G. Effects of tea on the absorption of pharmacological doses of an oral iron preparation. Isr J Med Sci (1982) 18, 547.
Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord (1992) 16, 269–77.
Lo ACT, Chan K, Yeung JHK, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and dynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet (1992) 17, 257–62.
Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy (1999) 19, 870–6.
Ellis GR, Stephens MR. Untitled report. BMJ (1999) 319, 650.
Sunter W. Warfarin and garlic. Pharm J (1991) 246, 722.
Shalansky S, Neall E, Lo M, Abd-Elmessih E, Vickars L, Lynd L. The impact of complementary and alternative medicine use on warfarin-related adverse outcomes. Pharmacotherapy (2002) 22, 1345.
Argento A, Tiraferri E, Marzaloni M. Anticoagulanti orali e piante medicinali. Una interazione emergente. Ann Ital Med Int (2000) 15, 139–43.
Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q 10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost (2002) 87, 1075–6.
Lai C-F, Chang C-C, Fu C-H, Chen C-M. Evaluation of the interaction between warfarin and ginkgo biloba extract. Pharmacotherapy (2002) 22, 1326.
Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology (2003) 99, 111.
Chiffoleau A, Huguenin H, Veyrac G, Argaiz V, Dupe D, Kayser M, Bourin M, Jolliet P. Interaction entre mélilot et acénocoumarol ?     Therapie (2001) 56, 321–7.
Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, Langheinrich M, Hübner W-D. Interaction of St John’s wort extract with phenprocoumon. Eur J Clin Pharmacol (1999) 55, A22.
Bon S, Hartmann, Kuhn M. Johanniskraut: Ein Enzyminduktor? Schweiz Apothekerzeitung (1999) 16, 535–6.
Bransgrove LL. Interaction between warfarin and a vitamin K-containing nutritional supplement: a case report. J Herb Pharmacother (2001) 1, 85–89.
